These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 11125568)

  • 1. A peritoneal dialysis solution prepared from a three-compartment bag: biological and clinical effects.
    Cappelli G; Amore A; Bandiani G; Cancarini G; Coppo R; Feriani M; Dell'Aquila R; Saffioti S; Spisni C; Stingone A; Orazi E; Ballocchi S; Renaux JL
    Contrib Nephrol; 2001; (131):97-106. PubMed ID: 11125568
    [No Abstract]   [Full Text] [Related]  

  • 2. Strategy for preventing peritoneal dialysis failure.
    Cancarini G
    Contrib Nephrol; 2001; (131):114-24. PubMed ID: 11125557
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: effects of low-glucose degradation product solution on peritoneal membrane characteristics in peritoneal dialysis patients: a 3-year follow-up study.
    Ahmadi F
    Iran J Kidney Dis; 2014 Mar; 8(2):158-60. PubMed ID: 24685741
    [No Abstract]   [Full Text] [Related]  

  • 4. Peritoneal transport in long-term peritoneal dialysis patients and its relation with AGEs.
    Feriani M
    Contrib Nephrol; 2001; (131):74-81. PubMed ID: 11125565
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical research in peritoneal dialysis.
    Coles GA
    Contrib Nephrol; 2001; (131):125-31. PubMed ID: 11125558
    [No Abstract]   [Full Text] [Related]  

  • 6. Exogenous uptake of carbonyl stress compounds promoting AGE formation from peritoneal dialysis fluids.
    Wieslander A; Linden T; Musi B; Järkelid L; Speidel R; Beck W; Henle T; Deppisch R
    Contrib Nephrol; 2001; (131):82-9. PubMed ID: 11125566
    [No Abstract]   [Full Text] [Related]  

  • 7. GDPs and AGEs: local and systemic effects in PD patients.
    Ledebo I; Wieslander A; Deppisch R
    Contrib Nephrol; 2003; (140):38-46. PubMed ID: 12800342
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of low glucose degradation product dialysis solution on epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis patients.
    Do JY; Kim YL; Park JW; Cho KH; Kim TW; Yoon KW; Kim CD; Park SH; Han JH; Song IH
    Perit Dial Int; 2005 Feb; 25 Suppl 3():S22-5. PubMed ID: 16048250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term peritoneal dialysis-impact of peritoneal membrane changes and newer solutions.
    Krediet RT
    Int J Artif Organs; 1998 Aug; 21(8):437-9. PubMed ID: 9803343
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term results with low glucose degradation product content in peritoneal dialysis fluids.
    Rippe B; Wieslander A; Musi B
    Contrib Nephrol; 2003; (140):47-55. PubMed ID: 12800343
    [No Abstract]   [Full Text] [Related]  

  • 11. Lactate-buffered and bicarbonate-buffered solutions with less glucose degradation products in a two-chamber system.
    Passlick-Deetjen J; Lage C
    Perit Dial Int; 2000; 20 Suppl 2():S42-7. PubMed ID: 10911642
    [No Abstract]   [Full Text] [Related]  

  • 12. The dialytic failure of the peritoneal membrane.
    Lupo A; Rugiu C; Lapolla A; Maiorca P; Aricó CN; Bernich P; Marcantoni C; Brezzi B; Maschio G
    Contrib Nephrol; 2001; (131):90-6. PubMed ID: 11125567
    [No Abstract]   [Full Text] [Related]  

  • 13. Glucose degradation products increase apoptosis of human mesothelial cells.
    Amore A; Cappelli G; Cirina P; Conti G; Gambaruto C; Silvestro L; Coppo R
    Nephrol Dial Transplant; 2003 Apr; 18(4):677-88. PubMed ID: 12637635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of transforming growth factor-beta 1 gene overexpression as a strategy to prevent fibrosis.
    Gambaro G; Weigert C; Ceol M; Schleicher ED
    Contrib Nephrol; 2001; (131):107-13. PubMed ID: 11125556
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of glucose in peritoneal dialysis: saint or sinner?
    Sitter T; Sauter M
    Perit Dial Int; 2005; 25(5):415-25. PubMed ID: 16178471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritoneal dialysis in diabetic patients.
    Bertoli M; Bonfante L; Gambaro G; Cara M; Virgilio B; D'Angelo A
    Contrib Nephrol; 2001; (131):51-60. PubMed ID: 11125563
    [No Abstract]   [Full Text] [Related]  

  • 17. Peritoneal dialysis solutions disturb the balance of apoptosis and proliferation of peritoneal cells in chronic dialysis model.
    Zheng Z; Ye R; Yu X; Bergström J; Lindholm B
    Adv Perit Dial; 2001; 17():53-7. PubMed ID: 11510297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Membrane viability in the long-term peritoneal dialysis patient.
    Schreiber MJ
    Perit Dial Int; 1997; 17 Suppl 3():S19-24. PubMed ID: 9304652
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of glucose-free dialysis solutions on human peritoneal mesothelial cells.
    Chang JM; Lin SP; Lai YH; Chen HC
    Am J Nephrol; 2007; 27(2):206-11. PubMed ID: 17377374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritoneal dialysis solution induces apoptosis of mesothelial cells.
    Yang AH; Chen JY; Lin YP; Huang TP; Wu CW
    Kidney Int; 1997 Apr; 51(4):1280-8. PubMed ID: 9083298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.